- Home
- BKYI vs THAR Comparison
BKYI vs THAR Comparison
Compare BKYI & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- THAR
- Stock Information
- Founded
- BKYI 1993
- THAR 2017
- Country
- BKYI United States
- THAR United States
- Employees
- BKYI N/A
- THAR N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- THAR Health Care
- Exchange
- BKYI Nasdaq
- THAR Nasdaq
- Market Cap
- BKYI 3.8M
- THAR 4.0M
- IPO Year
- BKYI 1997
- THAR 2022
- Fundamental
- Price
- BKYI $0.75
- THAR $1.29
- Analyst Decision
- BKYI
- THAR Strong Buy
- Analyst Count
- BKYI 0
- THAR 1
- Target Price
- BKYI N/A
- THAR $17.00
- AVG Volume (30 Days)
- BKYI 391.9K
- THAR 135.2K
- Earning Date
- BKYI 03-27-2025
- THAR 05-08-2025
- Dividend Yield
- BKYI N/A
- THAR N/A
- EPS Growth
- BKYI N/A
- THAR N/A
- EPS
- BKYI N/A
- THAR N/A
- Revenue
- BKYI $6,929,571.00
- THAR N/A
- Revenue This Year
- BKYI $1.96
- THAR N/A
- Revenue Next Year
- BKYI $9.65
- THAR N/A
- P/E Ratio
- BKYI N/A
- THAR N/A
- Revenue Growth
- BKYI N/A
- THAR N/A
- 52 Week Low
- BKYI $0.52
- THAR $1.20
- 52 Week High
- BKYI $3.68
- THAR $7.13
- Technical
- Relative Strength Index (RSI)
- BKYI 30.45
- THAR 35.72
- Support Level
- BKYI $0.75
- THAR $1.20
- Resistance Level
- BKYI $1.20
- THAR $1.65
- Average True Range (ATR)
- BKYI 0.11
- THAR 0.15
- MACD
- BKYI -0.03
- THAR -0.00
- Stochastic Oscillator
- BKYI 7.92
- THAR 18.40
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.